Skip to main content
Figure 3. | BMC Infectious Diseases

Figure 3.

From: Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial

Figure 3.

Solicited local and systemic adverse reactions graded according to severity in different age groups. Shown are the percentages of participants in whom solicited local or systemic adverse reactions occurred within 30 days after a booster dose of ZF2001 in the safety set (SS). The age groups observed included 3-5 years, 6-11 years, 12-17 years and 3-17 years of age (all participants)

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us